Stockreport

SAB Biotherapeutics Announces Departure of Chief Financial Officer [Yahoo! Finance]

SAB Biotherapeutics, Inc.  (SABS) 
PDF a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of T1D, today announced that effective June [Read more]